Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL28585498 | 0.89 | CA12 (0.52) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL4418096 | 0.85 | CA1 (0.49) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL19332220 | 0.85 | DHFR (0.60) | KMT2AMEN1CA1CA2MMP1 | |
| SCHEMBL6495011 | 0.85 | STS (0.61) | NFKB1CA1CA2MMP1MMP2 | |
| SCHEMBL4432604 | 0.85 | EGFR (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5394506 | 0.85 | CA1 (0.57) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL38663094 | 0.84 | KMT2A (0.71) | KMT2AMEN1CA1CA2LMNA | |
| SCHEMBL25123104 | 0.84 | SMN1; SMN2 (0.54) | KMT2ACA1CA2MMP1MMP2 | |
| SCHEMBL10983625 | 0.84 | KMT2A (0.50) | NFKB1NFKB2RELAKMT2AMEN1 | |
| SCHEMBL20047462 | 0.84 | PPARA (0.47) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745119-A1 | ISOCYANATE COMPOSITION | Hanwha Solutions Corporation (KR) | 2026-05-20 | — | — | EP | claimed |
| EP-4676477-A1 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | ELI LILLY AND COMPANY (US) | 2026-01-14 | — | — | EP | claimed |
| WO-2025042219-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2025-02-27 | — | — | WO | claimed |
| CN-119060043-A | Preparation method and application of benzimidazole-1-yl methanol kernel-based compound | 上海科思微半导体材料有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-119060044-A | Compound based on benzimidazole-1-yl methanol kernel and preparation method and application thereof | 上海科思微半导体材料有限公司 | 2024-12-03 | — | — | CN | claimed |
| WO-2024191686-A1 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | ELI LILLY AND COMPANY (US) | 2024-09-19 | — | — | WO | claimed |
| US-20240307349-A1 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | LILLY CO ELI (US) | 2024-09-19 | — | — | US | claimed |
| CN-117586497-B | Preparation method of printing ink based on amino-terminated hyperbranched polyamide | 江苏众立生包装科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-117586497-A | Preparation method of printing ink based on amino-terminated hyperbranched polyamide | 江苏众立生包装科技有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | claimed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| US-20200099097-A1 | GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | claimed |
| CN-105585511-B | (R) preparation method of N tertbutyloxycarbonyls biphenyl Propanolamine | 浙江大学 | 2017-05-31 | — | — | CN | claimed |
| CN-105585511-A | Preparation method of (R)-N-t-butyloxycarboryl biphenyl alaninol | UNIV ZHEJIANG | 2016-05-18 | — | — | CN | claimed |
| WO-2013065066-A1 | PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | claimed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | claimed |
| EP-4745119-A1 | ISOCYANATE COMPOSITION | Hanwha Solutions Corporation (KR) | 2026-05-20 | — | — | EP | disclosed |
| US-12581891-B2 | Substrate processing method, substrate processing device, and processing fluid | SCREEN Holdings Co., Ltd. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20250161461-A1 | TARGETING LIGAND CONTAINING N-ACETYLGALACTOSAMINE | RONA BIOSCIENCE, LIMITED (CN) | 2025-05-22 | — | — | US | disclosed |
| CN-119980266-A | Method for electrochemical catalysis of direct amination reaction of aromatic alkane hydrocarbon bond | 南京工业大学 | 2025-05-13 | — | — | CN | disclosed |
| EP-4541893-A1 | SIRNA MOLECULE FOR REGULATING PCSK9 GENE ACTIVITY | Rona Bioscience, Limited (HK) | 2025-04-23 | — | — | EP | disclosed |
| US-20250110407-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR CORPORATION (JP) | 2025-04-03 | — | — | US | disclosed |
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| CN-119585431-A | SiRNA molecules for regulating and controlling ANGPTL3 gene activity | 大睿生物医药科技(上海)有限公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025042219-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2025-02-27 | — | — | WO | disclosed |
| WO-2025042730-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119487191-A | SiRNA molecule for regulating PCSK9 gene activity | 大睿生物医药科技(上海)有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119060043-A | Preparation method and application of benzimidazole-1-yl methanol kernel-based compound | 上海科思微半导体材料有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119060044-A | Compound based on benzimidazole-1-yl methanol kernel and preparation method and application thereof | 上海科思微半导体材料有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240352059-A1 | LIVER X RECEPTOR MODULATORS | UNIVERSITY OF HEALTH SCIENCES AND PHARMACY IN ST. LOUIS | 2024-10-24 | — | — | US | disclosed |
| US-20240307349-A1 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | LILLY CO ELI (US) | 2024-09-19 | — | — | US | disclosed |
| CN-117586497-B | Preparation method of printing ink based on amino-terminated hyperbranched polyamide | 江苏众立生包装科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240142876-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-05-02 | — | — | US | disclosed |
| US-20240105451-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD AND COMPOSITION | JSR CORPORATION (JP) | 2024-03-28 | — | — | US | disclosed |
| CN-117586497-A | Preparation method of printing ink based on amino-terminated hyperbranched polyamide | 江苏众立生包装科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2024032608-A1 | SIRNA MOLECULE FOR REGULATING ANGPTL3 GENE ACTIVITY | 大睿生物医药科技(上海)有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024002006-A1 | NUCLEOTIDE SUBSTITUTE HAVING ENHANCED STABILITY | 大睿生物医药科技(上海)有限公司 | 2024-01-04 | — | — | WO | disclosed |
| WO-2024002093-A1 | SIRNA FOR INHIBITING APOLIPOPROTEIN C3 EXPRESSION | 大睿生物医药科技(上海)有限公司 | 2024-01-04 | — | — | WO | disclosed |
| WO-2023241591-A1 | SIRNA MOLECULE FOR REGULATING PCSK9 GENE ACTIVITY | 大睿生物医药科技(上海)有限公司 | 2023-12-21 | — | — | WO | disclosed |
| WO-2023199881-A1 | METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE AND RESIST UNDERLAYER FILM FORMING COMPOSITION | JSR株式会社 | 2023-10-19 | — | — | WO | disclosed |
| CN-111562720-B | Photo-sensitized chemically amplified resist material, pattern forming method, semiconductor device, mask for lithography, and template for nanoimprint | 东京毅力科创株式会社 | 2023-09-29 | — | — | CN | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230268172-A1 | SUBSTRATE PROCESSING METHOD, SUBSTRATE PROCESSING DEVICE, AND PROCESSING FLUID | SCREEN Holdings Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| CN-111315744-B | Heteroaryl tetrahydropyridine compound, preparation method, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116134586-A | Substrate processing method, substrate processing apparatus, and processing liquid | 株式会社斯库林集团 | 2023-05-16 | — | — | CN | disclosed |
| CN-114539304-B | Synthesis method and application of 1,3-azasilane compound | 四川大学 | 2023-03-31 | — | — | CN | disclosed |
| US-11557793-B2 | Flexible all-solid-state lithium-ion secondary battery having gelable system containing lithium salt and ether compound, and preparation method thereof | BEIJING NORMAL UNIVERSITY (CN) | 2023-01-17 | — | — | US | disclosed |
| US-11545696-B2 | Gelable system and uses thereof in lithium-air batteries, organic supercapacitors or capacitor batteries | BEIJING NORMAL UNIVERSITY (CN) | 2023-01-03 | — | — | US | disclosed |
| WO-2022259885-A1 | SEMICONDUCTOR SUBSTRATE PRODUCTION METHOD AND COMPOSITION FOR FORMING RESIST UNDERLAYER FILM | JSR株式会社 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022244682-A1 | SEMICONDUCTOR SUBSTRATE MANUFACTURING METHOD, AND RESIST BASE FILM FORMING COMPOSITION | JSR株式会社 | 2022-11-24 | — | — | WO | disclosed |
| WO-2022241404-A1 | LIVER X RECEPTOR MODULATORS | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-11-17 | — | — | WO | disclosed |
| CN-114539304-A | Synthesis method and application of 1, 3-azasilane compounds | 四川大学 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022024709-A1 | SUBSTRATE PROCESSING METHOD, SUBSTRATE PROCESSING DEVICE, AND PROCESSING FLUID | 株式会社ＳＣＲＥＥＮホールディングス | 2022-02-03 | — | — | WO | disclosed |
| CN-109836360-B | Preparation method of edoxaban tosylate intermediate and intermediate compound | 南京恩泰医药科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-109836360-B | Preparation method of edoxaban tosylate intermediate and intermediate compound | 南京恩泰医药科技有限公司 | 2021-08-13 | — | — | CN | disclosed |
| CN-108962627-B | Organic system super capacitor or capacitance battery | 北京师范大学 | 2021-01-26 | — | — | CN | disclosed |
| EP-3109703-B1 | PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, AND METHOD FOR FORMING PATTERN USING SAME | TOKYO ELECTRON LTD (JP) | 2020-12-30 | — | — | EP | disclosed |
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | disclosed |
| CN-111562720-A | Photosensitizing chemically amplified resist material, method for forming pattern, semiconductor device, mask for lithography, and template for nanoimprint | 东京毅力科创株式会社 | 2020-08-21 | — | — | CN | disclosed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | disclosed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | disclosed |
| US-20200099097-A1 | GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | disclosed |
| CN-109836360-A | A kind of preparation method and midbody compound of toluenesulfonic acid Yi Dushaban intermediate | 南京恩泰医药科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| CN-108962627-A | A kind of supercapacitor or capacitor batteries of organic system | 北京师范大学 | 2018-12-07 | — | — | CN | disclosed |
| CN-108963389-A | It is a kind of for lithium-air battery can gelling system and its preparation method and application | 北京师范大学 | 2018-12-07 | — | — | CN | disclosed |
| US-10073348-B2 | Resist-pattern-forming method and chemically amplified resist material | OSAKA UNIVERSITY (JP) | 2018-09-11 | — | — | US | disclosed |
| US-10073349-B2 | Chemically amplified resist material, pattern-forming method, compound, and production method of compound | OSAKA UNIVERSITY (JP) | 2018-09-11 | — | — | US | disclosed |
| US-10025187-B2 | Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting | TOKYO ELECTRON LIMITED (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10018911-B2 | Chemically amplified resist material and resist pattern-forming method | JSR CORPORATION (JP) | 2018-07-10 | — | — | US | disclosed |
| US-9989849-B2 | Chemically amplified resist material and resist pattern-forming method | JSR CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| US-9971247-B2 | Pattern-forming method | OSAKA UNIVERSITY (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2914613-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-22 | — | — | EP | disclosed |
| EP-2914598-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| CN-105585511-B | (R) preparation method of N tertbutyloxycarbonyls biphenyl Propanolamine | 浙江大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-105585511-B | (R) preparation method of N tertbutyloxycarbonyls biphenyl Propanolamine | 浙江大学 | 2017-05-31 | — | — | CN | disclosed |
| US-20170131634-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-20170131633-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170052448-A1 | RESIST-PATTERN-FORMING METHOD AND CHEMICALLY AMPLIFIED RESIST MATERIAL | OSAKA UNIVERSITY (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170052449-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND | OSAKA UNIVERSITY (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170052450-A1 | PATTERN-FORMING METHOD | OSAKA UNIVERSITY (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3133444-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND | OSAKA UNIVERSITY (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133445-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL | OSAKA UNIVERSITY (JP) | 2017-02-22 | — | — | EP | disclosed |
| EP-3109703-A1 | PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, METHOD FOR FORMING PATTERN USING SAME, SEMICONDUCTOR DEVICE, MASK FOR LITHOGRAPHY, AND TEMPLATE FOR NANOIMPRINTING | Tokyo Electron Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20160357103-A1 | PHOTOSENSITIZATION CHEMICAL-AMPLIFICATION TYPE RESIST MATERIAL, METHOD FOR FORMING PATTERN USING SAME, SEMICONDUCTOR DEVICE, MASK FOR LITHOGRAPHY, AND TEMPLATE FOR NANOIMPRINTING | TOKYO ELECTRON LIMITED (JP) | 2016-12-08 | — | — | US | disclosed |
| CN-105585511-A | Preparation method of (R)-N-t-butyloxycarboryl biphenyl alaninol | UNIV ZHEJIANG | 2016-05-18 | — | — | CN | disclosed |
| CN-105585511-A | Preparation method of (R)-N-t-butyloxycarboryl biphenyl alaninol | UNIV ZHEJIANG | 2016-05-18 | — | — | CN | disclosed |
| US-9334279-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150329547-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-19 | — | — | US | disclosed |
| US-20150284409-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2914613-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2914598-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014070964-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014071007-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| CN-101711250-B | Benzenesulfonamide methylene substituted mercapto pyrrolidine carbapenem derivatives | KBP BIOSCIENCES CO LTD | 2014-04-09 | — | — | CN | disclosed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| WO-2013065066-A1 | PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013065066-A1 | PROCESSES FOR PREPARING 4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6- DIHYDRO [L,2,41-TRIAZOLO[43-A]PYRAZIN-7(8H)-YL]-L-(2,4,5- TRIFLUOROPHENYL)BUTAN-2-AMINE | CADILA HEALTHCARE LIMITED (IN) | 2013-05-10 | — | — | WO | disclosed |
| US-8367646-B2 | Steroid compounds and treatment methods | Harbor Therapeutics, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| CN-102859439-A | Positive radiation-sensitive composition, interlayer insulating film for display element, and formation method for same | JSR CORP | 2013-01-02 | — | — | CN | disclosed |
| EP-2477976-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | HARBOR BIOSCIENCES, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8076316-B2 | Steroid compounds and formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| EP-1955700-B9 | Therapeutic treatment of androgen receptor driven conditions | HARBOR BIOSCIENCES INC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2322182-A1 | Androstenol derivatives as androgen receptor modulator | Harbor BioSciences, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20110098260-A1 | Steroid Compounds and Formulations | HARBOR BIOSCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011032277-A1 | QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-24 | — | — | WO | disclosed |
| EP-1955700-B1 | Therapeutic treatment of androgen receptor driven conditions | HARBOR BIOSCIENCES INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7906497-B2 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-7863261-B2 | Breast and prostate cancer treatment method | HARBOR BIOSCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100240633-A1 | Cancer treatment methods | HARBOR BIOSCIENCES, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-RE41614-E1 | Synthetic analogs of ecteinascidin-743 | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-08-31 | — | — | US | disclosed |
| US-7776845-B2 | Pharmaceutical compositions | HARBOR BIOSCIENCES, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| CN-101711250-A | Benzenesulfonamide methylene substituted mercapto pyrrolidine carbapenem derivatives | KBP BIOMEDICAL CO LTD | 2010-05-19 | — | — | CN | disclosed |
| US-7696189-B1 | Prostate and breast cancer treatment | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7691835-B2 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2135611-A1 | Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy | Hollis-Eden Pharmaceuticals Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| CN-101466666-A | Process for preparing organic oxides | TAKEDA PHARMACEUTICAL (JP) | 2009-06-24 | — | — | CN | disclosed |
| EP-2003116-A9 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090054655-A1 | Process for the Production of Organic Oxides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2009-01-22 | — | — | US | disclosed |
| CN-100448844-C | Histone deacetylase inhibitors | METHYLGENE INC (CA) | 2009-01-07 | — | — | CN | disclosed |
| EP-2003116-A2 | PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES | Takeda Pharmaceutical Company Limited (JP) | 2008-12-17 | — | — | EP | disclosed |
| EP-1223941-B1 | THERAPEUTIC TREATMENTS FOR BLOOD CELL DEFICIENCIES USING SREROIDS | HOLLIS EDEN PHARMACEUTICALS (US) | 2008-11-05 | — | — | EP | disclosed |
| EP-1955700-A2 | Therapeutic treatment of androgen receptor driven conditions | Hollis-Eden Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176823-A1 | Breast and Prostate Cancer Treatment Method | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080058301-A1 | Formulations | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080021006-A1 | Pharmaceutical Compositions | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-7282608-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2007-10-16 | — | — | US | disclosed |
| EP-1832598-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| EP-1419126-B1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIV PITTSBURGH (US) | 2006-11-02 | — | — | EP | disclosed |
| CN-1837231-A | Immunomodulatory steroids, in particular the hemihydrate of 16, alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2006-09-27 | — | — | CN | disclosed |
| US-20060079492-A1 | Compositions and treatment methods | BIOVIE INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060063749-A1 | Pharmaceutical compositions and treatment methods - 5 | BIOVIE INC. | 2006-03-23 | — | — | US | disclosed |
| CN-1243767-C | Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | METHYLGENE, INC. (CA) | 2006-01-26 | — | — | US | disclosed |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | BIOVIE INC. | 2005-12-22 | — | — | US | disclosed |
| CN-1705635-A | Inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2005-12-07 | — | — | CN | disclosed |
| US-20050256095-A1 | Asthma and colitis treatment methods | BIOVIE INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1551795-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2005-07-13 | — | — | EP | disclosed |
| US-20050075321-A1 | Neurological disorder treatment methods | BIOVIE INC. | 2005-04-07 | — | — | US | disclosed |
| US-6855725-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | BIOVIE INC. | 2004-11-04 | — | — | US | disclosed |
| US-6806357-B1 | REACTING THE ALCOHOL AND A NUCLEOPHILE WITH AN AZODICARBOXYLATE AND A PHOSPHINE. AT LEAST ONE OF THE AZODICARBOXYLATE AND THE PHOSPHINE INCLUDES AT LEAST ONE FLUOROUS TAG | UNIVERSITY OF PITTSBURGH | 2004-10-19 | — | — | US | disclosed |
| US-20040116359-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1419126-A1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIVERSITY OF PITTSBURGH (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2004035525-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2004-04-29 | — | — | WO | disclosed |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | BLEISCH THOMAS JOHN (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1351952-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003016246-A1 | FLUOROUS NUCLEOPHILIC SUBSTITUTION OF ALCOHOLS AND REAGENTS FOR USE THEREIN | UNIVERSITY OF PITTSBURGH (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1228083-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1223941-A2 | THERAPEUTIC TREATMENTS COMPRISING ADMINISTRATOIN OF CERTAIN STEROIDS FOR BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002053556-A2 | PYRROLIDINYLMETHYL SUBSTITUTED DECAHYDROISOQUINOLINES AS EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-07-11 | — | — | WO | disclosed |
| CN-1355809-A | Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2002-06-26 | — | — | CN | disclosed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001030802-A2 | THERAPEUTIC TREATMENTS COMPRISING ADMINISTRATION OF CERTAIN STEROIDS FOR BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001023405-A2 | THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| US-6187083-B1 | INK COMPOSITION COMPRISING SELECTED INK VEHICLE, AMIDE VISCOSITY MODIFIER, CONDUCTIVE SULFONATE SALT ALL HAVING MELTING POINTS WITHIN SPECIFIED RANGE, COLORANT, OPTIONAL ANTIOXIDANT AND ULTRAVIOLET ABSORBER | XEROX CORPORATION | 2001-02-13 | — | — | US | disclosed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| US-5654431-A | EXHIBIT SELECTIVITY TOWARDS 5-HYDROXYTRYPTAMINE RECEPTORS OF BRAIN CELLS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1997-08-05 | — | — | US | disclosed |
| EP-0662829-A1 | POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007480-A1 | POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994007480-A1 | POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (45 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10073348-B2 | Resist-pattern-forming method and chemically amplified resist material | XRCC6, XRCC5, BLM | NFKB1 2210/4885NFKB2 2932/4885RELA 809/4885 |
| US-20240307349-A1 | METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF | SSTR4, NPY4R, SSTR3 | NFKB1 3897/4885NFKB2 4125/4885RELA 4179/4885 |
| US-20110098260-A1 | Steroid Compounds and Formulations | AR, NR5A1, CYP17A1 | NFKB1 557/4885NFKB2 767/4885RELA 447/4885 |
| US-10025187-B2 | Photosensitization chemical-amplification type resist material, method for forming pattern using same, semiconductor device, mask for lithography, and template for nanoimprinting | ASIC1, ASIC3, CLTA | NFKB1 3763/4885NFKB2 4084/4885RELA 4430/4885 |
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | NFKB1 306/4885NFKB2 869/4885RELA 529/4885 |
| US-20090023734-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC6 | NFKB1 899/4885NFKB2 1136/4885RELA 469/4885 |
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | NFKB1 348/4885NFKB2 1056/4885RELA 615/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | NFKB1 178/4885NFKB2 467/4885RELA 499/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | NFKB1 474/4885NFKB2 526/4885RELA 884/4885 |
| US-20100240633-A1 | Cancer treatment methods | AR, KLK3, ACP3 | NFKB1 2191/4885NFKB2 2469/4885RELA 430/4885 |
| US-20150329547-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | NFKB1 1295/4885NFKB2 1425/4885RELA 611/4885 |
| US-20120071454-A1 | Steroid Compounds and Treatment Methods | AR, NR5A1, CYP17A1 | NFKB1 1311/4885NFKB2 1563/4885RELA 508/4885 |
| US-10073349-B2 | Chemically amplified resist material, pattern-forming method, compound, and production method of compound | RER1, POLR1A, FEM1B | NFKB1 2187/4885NFKB2 3384/4885RELA 1087/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | NFKB1 1629/4885NFKB2 2579/4885RELA 1076/4885 |
| US-20150284409-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | NFKB1 1295/4885NFKB2 1425/4885RELA 611/4885 |
| US-20050282732-A1 | Pharmaceutical compositions and treatment methods-7 | HSD17B7, IL17A, HSD3B1 | NFKB1 547/4885NFKB2 1197/4885RELA 879/4885 |
| US-20250161461-A1 | TARGETING LIGAND CONTAINING N-ACETYLGALACTOSAMINE | GALNT6, FUT6, GALNT1 | NFKB1 1735/4885NFKB2 1563/4885RELA 556/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | NFKB1 302/4885NFKB2 948/4885RELA 643/4885 |
| US-20250084087-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | NFKB1 2305/4885NFKB2 2218/4885RELA 3058/4885 |
| US-12581891-B2 | Substrate processing method, substrate processing device, and processing fluid | CUTA, MMP14, PLG | NFKB1 3690/4885NFKB2 3806/4885RELA 3733/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | NFKB1 1158/4885NFKB2 1579/4885RELA 747/4885 |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | HSD3B1, IL4, HSD17B7 | NFKB1 532/4885NFKB2 1099/4885RELA 919/4885 |
| US-20060079492-A1 | Compositions and treatment methods | MPL, HPGDS, THPO | NFKB1 1011/4885NFKB2 2078/4885RELA 595/4885 |
| US-20040220161-A1 | Pharmaceutical compositions and treatment methods-6 | HSD17B7, HSD3B1, NR5A1 | NFKB1 439/4885NFKB2 881/4885RELA 582/4885 |
| US-20040220114-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | NFKB1 402/4885NFKB2 1067/4885RELA 622/4885 |
| US-20050075321-A1 | Neurological disorder treatment methods | HSD17B1, HSD17B3, HSD3B1 | NFKB1 914/4885NFKB2 1869/4885RELA 2111/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | NFKB1 453/4885NFKB2 980/4885RELA 773/4885 |
| US-20080021006-A1 | Pharmaceutical Compositions | AR, KLK3, ACP3 | NFKB1 1439/4885NFKB2 1834/4885RELA 712/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | NFKB1 680/4885NFKB2 2031/4885RELA 1009/4885 |
| US-20080058301-A1 | Formulations | AR, KLK3, NR5A1 | NFKB1 1067/4885NFKB2 1446/4885RELA 623/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | NFKB1 505/4885NFKB2 1182/4885RELA 1349/4885 |
| US-20090054655-A1 | Process for the Production of Organic Oxides | OXSR1, CBR3, CYB5R3 | NFKB1 1746/4885NFKB2 2990/4885RELA 3645/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | NFKB1 680/4885NFKB2 2031/4885RELA 1009/4885 |
| US-20060063749-A1 | Pharmaceutical compositions and treatment methods - 5 | IL5, HSD3B1, NR5A1 | NFKB1 153/4885NFKB2 956/4885RELA 880/4885 |
| US-20080176823-A1 | Breast and Prostate Cancer Treatment Method | AR, KLK3, ACP3 | NFKB1 1662/4885NFKB2 2068/4885RELA 356/4885 |
| US-10018911-B2 | Chemically amplified resist material and resist pattern-forming method | SLC11A2, XRCC5, RAD54L | NFKB1 2561/4885NFKB2 3218/4885RELA 2091/4885 |
| US-20050256095-A1 | Asthma and colitis treatment methods | HSD3B1, HSD17B1, HSD11B1 | NFKB1 304/4885NFKB2 570/4885RELA 477/4885 |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | NFKB1 402/4885NFKB2 1067/4885RELA 622/4885 |
| US-20040063749-A1 | Excitatory amino acid receptor antagonists | SLC1A2, SLC1A1, SLC1A3 | NFKB1 1965/4885NFKB2 2227/4885RELA 2018/4885 |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | HSD3B1, HSD17B3, HSD3B2 | NFKB1 527/4885NFKB2 1047/4885RELA 696/4885 |
| US-20110230465-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | NFKB1 829/4885NFKB2 1293/4885RELA 1008/4885 |
| US-20240352059-A1 | LIVER X RECEPTOR MODULATORS | NR1H2, NR1H3, NR1H4 | NFKB1 798/4885NFKB2 770/4885RELA 316/4885 |
| US-20170052449-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL, PATTERN-FORMING METHOD, COMPOUND, AND PRODUCTION METHOD OF COMPOUND | RER1, POLR1A, FEM1B | NFKB1 2187/4885NFKB2 3384/4885RELA 1087/4885 |
| US-20060020131-A1 | Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents | HDAC1, AADAC, HDAC11 | NFKB1 1996/4885NFKB2 2129/4885RELA 620/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | NFKB1 304/4885NFKB2 874/4885RELA 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.